Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBEC…

Overview of attention for article published in BMC Cancer, July 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?

Article in Expert Opinion on Pharmacotherapy (April 2024)

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis

Article in Cancers (December 2023)

Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials

Article in Oncology Research and Treatment (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.